Lilly, Novo Nordisk, AstraZeneca and Roche Fuel a $17.1 Billion U.S. Manufacturing Surge to Meet Exploding Demand for Weight-Loss Treatments
DENVER, Colo. (247marketnews.com) — Eli Lilly (NYSE:LLY), Novo Nordisk (NYSE:NVO), AstraZeneca (NASDAQ:AZN), and Roche (OTCQX:RHHBY) are among the pharmaceutical leaders investing billions of dollars in new manufacturing capacity as obesity medicines emerge as one of the industry's biggest long-term growth markets. With four major U.S. manufacturing projects totaling $17.1 billion, drugmakers are positioning themselves to meet expanding demand for treatments that could generate trillions of dollars in cumulative sales over the next two decades.
Goldman Sachs Research forecasts global obesity-drug sales of $114 billion annually by 2030, with oral medicines accounting for 40% of the market.
If annual sales reached that level and remained unchanged from 2030 through 2049, cumulative revenue would total $2.28 trillion. That calculation is an illustrative 247MarketNews scenario, not a Goldman Sachs long-term forecast or a projection of profits.
The manufacturing commitments are already taking shape:
· Eli Lilly (NYSE: LLY) — Houston, Texas: A $6.5 billion facility will manufacture active ingredients for oral GLP-1 medicine orforglipron and other treatments. Lilly broke ground September 21 and expects more than 600 ongoing jobs and approximately 4,000 construction jobs.
· Novo Nordisk (NYSE: NVO) — Clayton, North Carolina: A $4.1 billion facility will expand production of injectable obesity and other chronic-disease medicines, with phased construction completion planned for 2027–2029.
· AstraZeneca (NYSE: AZN) — Albemarle County, Virginia: A $4.5 billion project will support oral GLP-1, other metabolic medicines and cancer therapies.
· Roche (OTCQX: RHHBY), through Genentech — Holly Springs, North Carolina: An approximately $2 billion plant will produce future metabolic and obesity treatments. Its structural framework was completed in August.
Together, these projects represent approximately $17.1 billion in announced investment. That figure covers entire facilities, including production capacity for medicines beyond obesity.
For host communities, the construction brings opportunities in engineering, manufacturing, laboratory operations and skilled trades. For drugmakers, the investment represents a long-term commitment to supplying a growing treatment market.
Whether sales ultimately reach the trillion-dollar cumulative threshold will depend on pricing, insurance coverage, competition, treatment adoption and how long patients remain on therapy.
About 24/7 Market News
In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
